Finally, the data used here were obtained from participants involved in tightly controlled clinical trials, and their demographic and clinical characteristics may not fully represent those of the broader population of patients with type 2 diabetes mellitus receiving SGLT-2 inhibitors in clinical practice. This evidence concerns the gene SLC5A2 and diabetes mellitus.